Our patented drug compound, COTI-2, has a major mechanism of action that is dependent on p53 gene mutation status in human cancer cells. This is important as drug treatment for p53 mutations represents a novel therapy and would be a first in class treatment for the drug company bringing COTI-2 to market.
COTI-2 is being developed as an oral treatment for solid tumors. COTI-2 up-regulates PI 3-kinase (PI3K) interacting protein and restores the wild type function to mutant p53 protein, leading to the degradation of the Akt protein kinase and restoration of apoptosis. Preclinical evaluation is ongoing and we expect to start clinical evaluation of COTI-2 in mid-2014.
For further information, please contact:
Sean Thompson, Strategic Consultant
Critical Outcome Technologies Inc.
700 Collip Circle, Suite 213
London, Ontario N6G 4X8
Tel: +1 905 399 1086